[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100597283":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":29,"locations":35,"responsibleParty":49,"collaborators":25,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":25,"eligibilityCriteria":59,"healthyVolunteers":55,"sex":60,"minAge":61,"maxAge":25,"enrollmentInfo":62,"targetDuration":25,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":25,"overallStatus":71,"whyStopped":25,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"Prince of Wales Hospital, Shatin, Hong Kong","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Denosumab group","ACTIVE_COMPARATOR","60mg subcutaneous Denosumab (1mL solution) every 6 months and intravenous placebo (100mL normal saline) once yearly",[13],"Drug: Denosumab (Prolia)",{"label":15,"type":16,"description":17,"interventionNames":18},"Zolendronic acid group","PLACEBO_COMPARATOR","5mg intravenous Zoledronic Acid (100mL solution) once yearly and subcutaneous placebo (1mL normal saline) every 6 months",[19],"Drug: Zoledronic acide (Aclasta)",[21,26],{"type":22,"name":23,"description":11,"armGroupLabels":24,"otherNames":25},"DRUG","Denosumab (Prolia)",[9],null,{"type":22,"name":27,"description":17,"armGroupLabels":28,"otherNames":25},"Zoledronic acide (Aclasta)",[15],[30],{"name":31,"role":32,"phone":33,"phoneExt":25,"email":34},"Ronald Man Yeung Wong","CONTACT","852 3505 1654","ronald.wong@cuhk.edu.hk",[36],{"facility":37,"status":25,"city":38,"state":25,"zip":25,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"The Chinese University of Hong Kong","Hong Kong","China","CN",{"type":42,"coordinates":43},"Point",[44,45],114.17469,22.27832,{"lat":45,"lon":44},[48],{"name":31,"role":32,"phone":33,"phoneExt":25,"email":34},{"type":50,"investigatorFullName":51,"investigatorTitle":52,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"PRINCIPAL_INVESTIGATOR","Ronald Man Yeung WONG","Clinical Associate Professor","100597283","phase-3-rankl-inhibition-to-combat-sarcopenia-in-hip-fracture-patients-100597283",false,"NCT07056478","RANKL Inhibition to Combat Sarcopenia in Hip Fracture Patients","RANKL Inhibition to Combat Sarcopenia in Hip Fracture Patients: A Pragmatic, Randomized Double-blind, Active-Controlled Trial","Inclusion Criteria:\n\n* Elderly aged 65 years or older\n* Diagnosed with sarcopenia following AWGS guidelines - low appendicular skeletal muscle mass measured by dual-energy x-ray absorptiometry (Cutoff: Male \\\u003C7.0kg\u002Fm2, and female \\\u003C5.4kg\u002Fm2) AND low handgrip strength (Cutoff: Male \\\u003C 28kg, Female \\\u003C18 kg) OR low physical performance (6-metre walk, cutoff: \\\u003C1.0m\u002Fs or 5-time chair stand test \\>=12s)\n* Diagnosed with a hip fracture from low-energy mechanism (e.g., falling from standing height) requiring an operation\n* Willing and able to comply with study protocol including follow-up evaluations.\n\nExclusion Criteria:\n\n* open fracture\n* multiple fractures\n* pathological fractures e.g., tumour, infection, etc.\n* history of medication or disease affecting bone metabolism e.g., hypo\u002Fhyperthyroidism\n* malignancy\n* chairbound or bedbound (unable to perform assessments)\n* serious cognitive problems e.g., severe dementia (unable to agree for consent) - renal impairment with glomerular filtration rate \\\u003C30 mL\u002Fmin\n* prior anti-osteoporotic medication e.g. bisphosphonates, denosumab, etc.\n* active infection,\n* severe malnutrition i.e. Mini Nutritional Assessment \\\u003C 17 points\n* serious neurological or neuromuscular conditions e.g. Parkinson's disease\n* uncontrolled chronic conditions e.g. poorly controlled diabetes mellitis\n* not anaesthetically fit for operation or conservative management","ALL","65 Years",{"count":63,"type":64},130,"ESTIMATED","INTERVENTIONAL",[67],"PHASE3","The objective of this study is to conduct a pragmatic, randomized, double-blind, active-controlled trial to assess the efficacy of receptor activator of nuclear factor-kB ligand (RANKL) inhibition in the treatment of sarcopenia in hip fractures.",[70],"Sarcopenia in Elderly","NOT_YET_RECRUITING","2025-06-29",{"date":74,"type":75},"2025-07-09","ACTUAL",{"date":77,"type":64},"2026-01-01",{"date":79,"type":64},"2030-01-01",{"name":5,"class":6},1]